More Than Half of Rheumatologists in Germany and Spain Reported they Tried Benlysta for their SLE Patients, According to a Recent BioTrends Report

More Than Half of Rheumatologists in Germany and Spain Reported they Tried Benlysta for their SLE Patients, According to a Recent BioTrends Report

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that rheumatologists in Germany and Spain indicated they have prescribed GlaxoSmithKline’s Benlysta (belimumab) for their patients, which is the first newly approved agent for systemic lupus erythematosus (SLE) in approximately 50 years. The findings come from the recent, report in which 198 online physician surveys from the EU5 countries—France, Germany, Italy, Spain and the U.K.—were analyzed.

Hydroxychloroquine (Sanofi-Aventis’ Plaquenil, generics) continues to be the most commonly used agent to treat SLE, regardless of disease severity and EU5 country. At the time this study was fielded, Benlysta, the newcomer to the market, was only approved for reimbursement in Germany and Spain. Rheumatologists from both Germany and Spain reported they have prescribed it for both their moderate and severe patients.

Following the presentation of a Benlysta product profile, initial reactions to the product across the EU5 countries tend to be moderate – very few rheumatologists in any country report negative initial reactions. However, most rheumatologists are unsure if the benefits outweigh the risks of the product. Rheumatologists in the U.K. are more likely than rheumatologists in other countries to report the risks of the product outweigh the benefits, whereas specialists from Germany are more likely to believe the benefits outweigh the risks. Interestingly, although the German Institute for Quality and Efficiency in Health Care (IQWiG) gave the opinion that the drug offered no additional benefit over standard of care prior to the time of this study’s fielding, physicians in Germany who have tried Benlysta reported they are moderately satisfied with it. Rheumatologists in Spain also reported this perception. It will be interesting to see what happens in the remaining EU5 countries, if and, when Benlysta receives reimbursement approval.

In addition to the report BioTrends has a full complement of reports focusing on lupus treatment in the United States: and(1 year post-launch).

is an annual, quantitative publication based on online physician surveys with rheumatologists fielded in July 2012 in the EU5 countries.

The primary objectives of the study are to:

BioTrends Research Group provides syndicated primary and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or . BioTrends is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

How long can one infusion of Gilead CAR-T drug Yescarta continue to help patients with refractory large B-cell lymphoma? Pretty long, Gilead showed.

AbbVie and Roche have been fielding their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan could keep chro

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.